PRIMARY STUDY
Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson’s Disease. Induced by MPTP.
Key Findings: These results indicate that BCP acts via multiple neuroprotective mechanisms in our murine model and suggest that BCP may be viewed as a potential treatment and/or preventative agent for PD.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Mexico, Spain, Switzerland
Year of Pub: 2017
Cannabinoids Studied: AM-x Synthetic Cannabinoids
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2
Ligands Studied: Anti-inflammatory cytokines, Dopamine, Pro-inflammatory cytokines
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Injection, Oral (Ingestion)
Dosing Regimen: BCP (10 mg/kg, i.p. and 10 mg/kg through an oral gavage)
Treatment Duration: 5 consecutive days
Clinical Relevance: BCP acts via multiple neuroprotective mechanisms in our murine model and may be viewed as a potential treatment and/or preventative agent for PD.
Additional Notes: Pharmacokinetic Study Data
Citation: Viveros-Paredes JM, et al. Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson's Disease Induced by MPTP. Pharmaceuticals (Basel). 2017; 10:(unknown pages). doi: 10.3390/ph10030060
Authors: Viveros-Paredes JM, González-Castañeda RE, Gertsch J, Chaparro-Huerta V, López-Roa RI, Vázquez-Valls E, Beas-Zarate C, Camins-Espuny A, Flores-Soto ME
